Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance

Acquired chemotherapeutic resistance of cancer cells can result from a Darwinistic evolution process in which heterogeneity plays an important role. In order to understand the impact of genetic heterogeneity on acquired resistance and second line therapy selection in metastatic melanoma, we sequence...

Descripción completa

Detalles Bibliográficos
Autores principales: Raaijmakers, Marieke I. G., Widmer, Daniel S., Narechania, Apurva, Eichhoff, Ossia, Freiberger, Sandra N., Wenzina, Judith, Cheng, Phil F., Mihic-Probst, Daniela, Desalle, Rob, Dummer, Reinhard, Levesque, Mitchell P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363577/
https://www.ncbi.nlm.nih.gov/pubmed/27791198
http://dx.doi.org/10.18632/oncotarget.12848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363577/
https://www.ncbi.nlm.nih.gov/pubmed/27791198
http://dx.doi.org/10.18632/oncotarget.12848

Ejemplares similares